Kaken Pharmaceutical Co (TSE:4521) Current Deferred Revenue: 円522 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4521 Kaken Pharmaceutical Co Ltd TSE:4521
65 GF Score
Price 円3,905.00
GF Value 円4,034.60
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Kaken Pharmaceutical Co Current Deferred Revenue?

Kaken Pharmaceutical Co TSE:4521 +0.51% 65 Current Deferred Revenue is 円522 Mil as of Mar. 2026. GuruFocus rates TSE:4521 with a GF Score™ of 65/100 and a GF Value™ of 円4,034.60 (Fairly Valued). The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Kaken Pharmaceutical Co's current deferred revenue for the quarter that ended in Mar. 2026 was 円522 Mil.

Kaken Pharmaceutical Co Current Deferred Revenue Related Terms

Kaken Pharmaceutical Co Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Kaken Pharmaceutical Co's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaken Pharmaceutical Co Current Deferred Revenue Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 43.00 22.00 522.00

Kaken Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.00 0.00 0.00 0.00 522.00
TSE:4521
65GF Score
Kaken Pharmaceutical Co Ltd TSE:4521
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of 円522 Mil mean?
Kaken Pharmaceutical Co (TSE:4521) has a Current Deferred Revenue of 円522 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Kaken Pharmaceutical Co and its competitors.
Is Kaken Pharmaceutical Co's Current Deferred Revenue too high?
Kaken Pharmaceutical Co's current Current Deferred Revenue is 円522 Mil. Overall, Kaken Pharmaceutical Co has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's Current Deferred Revenue compare to ZTS?
Kaken Pharmaceutical Co's Current Deferred Revenue of 円522 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Kaken Pharmaceutical Co and its competitors. Kaken Pharmaceutical Co's current Current Deferred Revenue is 円522 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co (TSE:4521) is currently considered Fairly Valued. The stock's GF Value™ is 円4,034.60, compared to a current price of 円3,905.00 — trading 3.2% below its estimated fair value. The current Current Deferred Revenue is 円522 Mil. Kaken Pharmaceutical Co's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Kaken Pharmaceutical Co (TSE:4521), the current Current Deferred Revenue is 円522 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kaken Pharmaceutical Co (TSE:4521) Overvalued in 2026?

Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be undervalued. The current stock price of 円3,905.00 is trading 3.2% below its estimated GF Value™ of 円4,034.60. GuruFocus considers Kaken Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4521:

  • Current Deferred Revenue: 円522 Mil
  • GF Value™: 円4,034.60 vs. price of 円3,905.00 (3.2% below fair value)
  • GF Score™: 65/100 with 2 warning signs

No single metric tells the full story. See the TSE:4521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kaken Pharmaceutical Co Business Description

Address 28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
65GF Score

Get the complete analysis for TSE:4521

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,905.00
Price
円4,034.60
GF Value